Category Archives: Parkinson’s Treatment

His findings spurred the establishment of human brain tissue banks, research into dopamine, and treatments of other diseases caused by low levels of neurotransmitters. Today, it is generally agreed that the initiation of the treatment of Parkinsons disease with L-dopa represented one of the triumphs of pharmacology of our time, Professor Hornykiewicz wrote in The History of Neuroscience in Autobiography, Volume IV (2004). Continue reading →

Newly developed MRI techniques can help neuroradiologists more effectively target and treat the area of the brain responsible for tremors in patients living with Parkinsons disease, leading to better surgery outcomes and fewer side effects. A research team, led by investigators from the University of Texas Southwestern (UTSW), has detailed three refined MRI methods neuroradiologists can use to precisely pinpoint the pea-sized region in the brains thalamus -- the ventral intermediate nucleas -- that is involved in movement. Providers use those MRI images with high-intensity focused ultrasound (HIFU) to burn away tissue causing movement problems Continue reading →

DALLAS June 14, 2020 Recently developed MRI techniques used to more precisely target a small area in the brain linked to Parkinsons disease and essential tremor may lead to better outcomes without surgery and with less risk of negative effects, a new study led by UT Southwestern researchers suggests. The study, published today in Brain, describes recently refined MRI methods designed to allow neuroradiologists to zero in on a pea-sized region in the brains thalamus involved in movement. Continue reading →

UCB Parkinsons Disease Treatment Market Scope Of The Report This report offers past, present as well as future analysis and estimates for the Parkinsons Disease Treatment market. The market estimates that are provided in the report are calculated through an exhaustive research methodology. Continue reading →

Parkinsons disease is a condition that causes the brain to become progressively more damaged over time, said the NHS. Continue reading →

INBRAIN Neuroelectronics, a spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2), the Barcelona Institute of Science and Technology (BIST) and ICREA, has received funding from Sabadell Asabys and Alta Life Sciences, as well as ICF and Finaves, which will allow the company to speed up the development of novel graphene-based implants to optimize the treatment of brain disorders, such as Parkinsons and epilepsy. INBRAIN Neuroelectronics was established in 2019 with the mission of developing brain-implants based on graphene technology for application in patients with epilepsy, Parkinsons, and other neuronal diseases. These smart devices, built around an innovative graphene electrode, will decode with high certainty neural signals from the brain and produce a therapeutic response adapted to the clinical condition of the specific patient. Continue reading →

Sinovac says early data show its Covid-19 vaccine generated Sinovac says early data show its Covid-19 vaccine generated immune responses Immunity to the coronavirus remains a mystery. Scientists are Immunity to the coronavirus remains a mystery. Continue reading →

COVID-19 Impact on Parkinsons Disease Treatment Market, Global Research Reports 2020-2021 In 2019, the global COVID-19 Impact on Parkinsons Disease Treatment Market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026. Continue reading →

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. Continue reading →

May 29, 2020 09:20 ET | Source: Minerva Neurosciences, Inc photo-release PANSS Negative Symptoms Factor Score (Marder) Change from Baseline (MMRM) (ITT Population) PSP Total Score Change from Baseline (MMRM) (ITT Population) WALTHAM, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the Phase 3 trial of roluperidone to treat negative symptoms in schizophrenia did not meet its primary (reduction in PANSS Marder Negative Symptoms Factor Score or NSFS) and key secondary (improvement in the Personal and Social Performance Scale Total Score or PSP) endpoints Continue reading →